AGEN1181: A Study of Botensilimab (AGEN1181) for the Treatment of Advanced Melanoma
Current standard treatment for patients with stage 3 or stage 4 advanced cutaneous melanoma is immunotherapy, with either pembrolizumab, or nivolumab with or without ipilimumab.This trial aims to investigate if a new treatment called botensilimab is effective at treating patients with advanced melanoma who have a had disease progression during or after treatment with standard of care immunotherapy. The trial also aims to look at how well patients tolerate treatment with botensilimab, for [...]
Locations: Mount Vernon Cancer Centre